Toshifumi Tsujiuchi Selected Research

Lysophosphatidic Acid Receptors

1/2022	Effects of lysophosphatidic acid (LPA) signaling via LPA receptors on cellular functions associated with ATP reduction in osteosarcoma cells treated with ethidium bromide.
11/2020	Cooperation of G12/13 and Gi proteins via lysophosphatidic acid receptor-2 (LPA2) signaling enhances cancer cell survival to cisplatin.
6/2020	Lysophosphatidic acid receptor-2 (LPA2)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs.
1/2020	LPA5-mediated signaling induced by endothelial cells and anticancer drug regulates cellular functions of osteosarcoma cells.
1/2019	Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA5 in melanoma cells treated with anticancer drugs.
8/2018	Promotion of cell-invasive activity through the induction of LPA receptor-1 in pancreatic cancer cells.
2/2018	Effects of LPA1 and LPA6 on the regulation of colony formation activity in colon cancer cells treated with anticancer drugs.
1/2018	Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells.
1/2018	Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells.
1/2018	Involvement of LPA receptor-5 in the enhancement of cell motile activity by phorbol ester and anticancer drug treatments in melanoma A375 cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toshifumi Tsujiuchi Research Topics

Disease

49	Neoplasms (Cancer) 01/2022 - 02/2002
18	Adenocarcinoma 03/2014 - 10/2002
16	Adenocarcinoma of Lung 08/2011 - 10/2002
15	Carcinogenesis 03/2014 - 04/2004
12	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 02/2002
9	Hepatocellular Carcinoma (Hepatoma) 04/2013 - 02/2002
6	Sarcoma (Soft Tissue Sarcoma) 08/2014 - 09/2007
5	Colonic Neoplasms (Colon Cancer) 02/2021 - 12/2010
5	Melanoma (Melanoma, Malignant) 06/2020 - 01/2010
5	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2005
5	Pancreatic Neoplasms (Pancreatic Cancer) 08/2018 - 10/2012
4	Fibrosarcoma 01/2018 - 01/2010
4	Pain (Aches) 12/2017 - 05/2007
4	Hyperalgesia 12/2017 - 05/2007
4	Malignant Fibrous Histiocytoma 01/2008 - 02/2002
3	Breast Neoplasms (Breast Cancer) 08/2018 - 01/2010
3	Carcinoma (Carcinomatosis) 03/2014 - 02/2002
3	Neuroblastoma 06/2012 - 01/2012
3	Body Weight (Weight, Body) 07/2007 - 05/2002
2	Pancreatitis 12/2017 - 05/2007
2	Cystitis 04/2014 - 10/2012
2	Adenoma (Adenomas) 02/2008 - 02/2002
2	Fibrosis (Cirrhosis) 02/2002 - 02/2002
1	Necrosis 01/2022
1	Ovarian Neoplasms (Ovarian Cancer) 11/2017
1	Visceral Pain 04/2014
1	Nociceptive Pain 04/2014
1	Inflammation (Inflammations) 04/2014
1	Edema (Dropsy) 04/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2014
1	Liver Neoplasms (Liver Cancer) 04/2013

Drug/Important Bio-Agent (IBA)

32	Lysophosphatidic Acid ReceptorsIBA 01/2022 - 10/2006
30	lysophosphatidic acidIBA 01/2022 - 05/2008
15	diisopropanolnitrosamineIBA 03/2014 - 10/2002
11	Biological ProductsIBA 01/2018 - 02/2002
10	hydrogen sulfite (bisulfite)IBA 08/2011 - 08/2005
8	CDAA (Randox)IBA 10/2011 - 02/2002
7	nitrosobis(2-oxopropyl)amine (NBOP)IBA 02/2012 - 02/2003
6	Cisplatin (Platino)FDA LinkGeneric 11/2020 - 03/2016
6	Pharmaceutical PreparationsIBA 01/2020 - 03/2016
6	Drinking WaterIBA 03/2014 - 02/2006
6	Amino Acids FDA Link 10/2011 - 02/2002
6	Choline (Choline Chloride)IBA 10/2011 - 02/2002
6	RNA (Ribonucleic Acid)IBA 10/2007 - 04/2004
5	Proteins (Proteins, Gene)FDA Link 11/2020 - 02/2002
4	GTP-Binding Proteins (G-Protein)IBA 11/2020 - 03/2016
4	NucleotidesIBA 01/2010 - 02/2003
4	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2007 - 05/2002
3	Nonesterified Fatty Acids (NEFA)IBA 04/2020 - 03/2016
3	CytokinesIBA 01/2012 - 02/2002
3	Colchicine FDA LinkGeneric 07/2007 - 05/2002
3	Cadherins (E-Cadherin)IBA 04/2007 - 10/2005
2	AgarIBA 02/2018 - 05/2008
2	Toll-Like Receptor 4IBA 12/2017 - 04/2014
2	Neutralizing AntibodiesIBA 12/2017 - 04/2014
2	ThrombomodulinIBA 12/2017 - 04/2014
2	CeruletideIBA 12/2017 - 05/2007
2	HMGB1 Protein (HMG1)IBA 12/2017 - 04/2014
2	Receptor for Advanced Glycation End ProductsIBA 12/2017 - 04/2014
2	LipidsIBA 01/2017 - 05/2008
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2014 - 10/2012
2	EnzymesIBA 10/2012 - 02/2002
2	Matrix Metalloproteinases (MMPs)IBA 02/2012 - 01/2012
2	Cytokine Receptors (Cytokine Receptor)IBA 01/2012 - 01/2012
2	extracellular matrix receptorIBA 01/2012 - 01/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2010 - 10/2007
2	Mitochondrial DNA (mtDNA)IBA 02/2008 - 10/2007
2	Cyclin-Dependent Kinase Inhibitor p16IBA 09/2007 - 01/2004
2	2-Acetylaminofluorene (2 Acetylaminofluorene)IBA 07/2007 - 05/2002
2	Carbon Tetrachloride (Tetrachloromethane)IBA 07/2007 - 05/2002
2	Transforming Growth Factor beta (TGF-beta)IBA 07/2006 - 02/2002
2	Protein Isoforms (Isoforms)IBA 02/2006 - 02/2002
1	Adenosine Triphosphate (ATP)IBA 01/2022
1	Ethidium (Ethidium Bromide)IBA 01/2022
1	matrigelIBA 08/2018
1	Tamoxifen FDA LinkGeneric 08/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	Phorbol EstersIBA 01/2018
1	Minocycline (Cyclops)FDA LinkGeneric 12/2017
1	Clodronic Acid (Clodronate)IBA 12/2017
1	ethyl pyruvateIBA 12/2017
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2017
1	Phosphotransferases (Kinase)IBA 11/2017
1	Therapeutic UsesIBA 11/2017
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2017
1	Indicators and Reagents (Reagents)IBA 04/2014
1	LipopolysaccharidesIBA 04/2014
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 04/2014
1	Thrombin FDA Link 04/2014
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 04/2013
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 10/2012
1	MibefradilIBA 10/2012

Therapy/Procedure

3	Chemoprevention 03/2014 - 01/2010
3	Hepatectomy 07/2007 - 05/2002
2	Therapeutics 11/2017 - 08/2013
2	Intraperitoneal Injections 07/2007 - 05/2002
1	Injections 12/2017
1	Subcutaneous Injections 03/2014
1	Oral Administration 03/2014
1	Radiotherapy 08/2013